Regimens of estrogen receptor antagonists
US12370181B2 · kind B2 · utility
0Cited by
32References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2020 |
| Grant date | Jul 29, 2025 |
| Priority date | — |
| Expiry date | Feb 16, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. In some embodiments, estrogen receptor antagonists provided herein are tetrahydro pyrido[3,4-b] indole compounds. In some embodiments, provided antagonists are complete estrogen receptor antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.